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Abstract
Background: Klotho was originally identified in a mutant mouse strain unable to express the gene that consequently
showed shortened life spans. In humans, low serum Klotho levels are related to the prevalence of cardiovascular diseases in
community-dwelling adults. However, it is unclear whether the serum Klotho levels are associated with signs of vascular
dysfunction such as arterial stiffness, a major determinant of prognosis, in human subjects with chronic kidney disease
(CKD).
Methods: We determined the levels of serum soluble Klotho in 114 patients with CKD using ELISA and investigated the
relationship between the level of Klotho and markers of CKD-mineral and bone disorder (CKD-MBD) and various types of
vascular dysfunction, including flow-mediated dilatation, a marker of endothelial dysfunction, ankle-brachial pulse wave
velocity (baPWV), a marker of arterial stiffness, intima-media thickness (IMT), a marker of atherosclerosis, and the aortic
calcification index (ACI), a marker of vascular calcification.
Results: The serum Klotho level significantly correlated with the 1,25-dihydroxyvitamin D level and inversely correlated with
the parathyroid hormone level and the fractional excretion of phosphate. There were significant decreases in serum Klotho
in patients with arterial stiffness defined as baPWV$1400 cm/sec, atherosclerosis defined as maximum IMT$1.1 mm and
vascular calcification scores of ACI.0%. The serum Klotho level was a significant determinant of arterial stiffness, but not
endothelial dysfunction, atherosclerosis or vascular calcification, in the multivariate analysis in either metabolic model, the
CKD model or the CKD-MBD model. The adjusted odds ratio of serum Klotho for the baPWV was 0.60 (p = 0.0075).
Conclusions: Decreases in the serum soluble Klotho levels are independently associated with signs of vascular dysfunction
such as arterial stiffness in patients with CKD. Further research exploring whether therapeutic approaches to maintain or
elevate the Klotho level could improve arterial stiffness in CKD patients is warranted.
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Introduction
Chronic kidney disease (CKD) may fundamentally underlie the
development of cardiovascular disease (CVD) and appears to be a
risk factor for CVD [1]. Patients with CKD are more likely to die
of CVD than to develop end-stage renal failure [2]. CKD leads to
increased levels of parathyroid hormone (PTH) and fibroblast
growth factor 23 (FGF23) and decreased levels of circulating 1,25-
dihydroxyvitamin D (1,25D) along with hypocalcemia, hyper-
phosphatemia, bone disease, vascular calcification and cardiovas-
cular morbidities collectively referred to as chronic kidney disease-
mineral and bone disorder (CKD-MBD) [3,4,5]. Recent reports
suggest that increased levels of FGF23 are a common manifesta-
tion of CKD that develop earlier than increased levels of
phosphate or PTH [6]. Additionally, the circulating FGF23 level
is independently correlated with endothelial dysfunction, possibly
due to asymmetrical dimethyl arginine, an endogenous inhibitor of
nitric oxide synthase [7].
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The Klotho gene, identified as an ‘aging suppressor’ gene in
mice, encodes a single-pass transmembrane protein that is
predominantly expressed in the distal tubular epithelial cells of
the kidneys, parathyroid glands and choroid plexus of the brain
[8,9,10,11]. Klotho was originally identified in a mutant mouse
strain that could not express the gene, which developed multiple
disorders resembling human aging and had a shortened life span
[10]. The aging phenotypes include atherosclerosis, endothelial
dysfunction, low bone mineral density, sarcopenia, skin atrophy
and impaired cognition. In an atherosclerotic mouse model, the in
vivo gene delivery of Klotho protects against endothelial dysfunc-
tion [12]. HMG-CoA reductase inhibition enhances the Klotho
protein expression in the kidneys and inhibits atherosclerosis in
rats with chronic blockade of nitric oxide synthase [13]. Emerging
evidence suggests that a deficiency of Klotho is an early biomarker
for CKD [14,15,16,17] and acute kidney injury [18]. There are
two forms of Klotho, a membrane form and a secreted form, and
each has distinct functions. Membrane Klotho acts as an obligate
co-receptor for FGF23, a bone-derived hormone that induces
phosphate excretion into the urine [19]. Secreted Klotho is
involved in the regulation of nitric oxide production in the
endothelium [20,21], maintenance of endothelial integrity and
permeability [22], calcium homeostasis in the kidneys [23] and
inhibition of intracellular insulin and insulin-like growth factor-1
signaling [24]. Secreted Klotho proteins are present in human sera
and cerebrospinal fluid, suggesting that post-translational cleavage
results in the release of Klotho proteins from the cell membrane
[25]. The extracellular domain of Klotho is clipped by the
membrane-anchored proteases ADAM10 and ADAM17 in order
to generate the secreted form [26].
Recently, a sensitive and specific assay was developed for the
measurement of soluble Klotho in humans [27]. Low serum
Klotho levels have been reported to be associated with poor
skeletal muscle strength [28] and the prevalence of CVD [29] and
all-cause mortality [30] in community-dwelling adults. The
expression of local vascular Klotho has been observed to decrease
in human arteries in patients with CKD compared to healthy
individuals [31]. Low serum Klotho levels have been reported in
patients with diabetes mellitus [32]. However, whether the serum
Klotho levels are closely related to signs of vascular dysfunction
such as arterial stiffness in patients with CKD is largely unknown.
We hypothesized that low serum Klotho levels are associated with
signs of vascular dysfunction such as arterial stiffness in patients
with CKD. To address this hypothesis, we measured the serum
Klotho levels and extensively investigated the relationship between
the serum Klotho level and signs of vascular dysfunction, including
endothelial dysfunction, arterial stiffness, atherosclerosis and
vascular calcification, in CKD patients. The data presented here
suggest that a decrease in the serum soluble Klotho level is an
independent biomarker of pronounced arterial stiffness in patients
with CKD.
Results
Patient characteristics
The baseline characteristics of the study population are shown
in Table 1. A total of 114 CKD patients with a median age of 58
(47–66) years were included in the study. The background causes
of CKD included 54 cases of glomerulonephritis (47%), 27 cases of
nephrosclerosis (24%), 13 cases of diabetic nephropathy (11%) and
20 cases of ‘‘other’’ (18%). A total of 83 patients were on
antihypertensive therapy (71 patients were being treated with
angiotensin receptor blockers (ARBs) or angiotensin converting
enzyme inhibitors (ACEIs), 58 with calcium channel antagonists
and 14 with other agents). Antihyperlipidemic agents were
administered to 35 patients and antidiabetic agents were
administered to 16 patients. The median serum Klotho level was
616.3 pg/mL, with an interquartile range of 460.0 to 755.5 pg/
mL, the value of which was comparable to that reported in a
previous study of CKD patients [17] and was higher than that in
hemodialysis patients [33,34].
Table 1. Baseline characteristics of the study subjects.
CKD patients (n=114)
Age (year) 58 (47–66)
Male sex, n (%) 72 (59%)
Cause of CKD, n
Glomerulonephritis 54 (47%)
Nephrosclerosis 27 (24%)
Diabetic nephropathy 13 (11%)
Others 20 (18%)
Current medication, n
ARBs/ACEIs 71 (62%)
CCBs 58 (51%)
MBP (mmHg) 94613
Serum calcium (mg/dL) 9.3 (9.0–9.5)
Serum phosphate (mg/dL) 3.660.7
FECa (%) 0.42 (0.26–0.70)
FEPi (%) 16.0 (11.2–29.6)
Intact PTH (pg/mL) 50 (38–84)
25D (ng/mL) 15 (12–23)
1,25D (pg/mL) 35 (24–50)
FGF23 (pg/mL) 44.4 (31.6–90.0)
Serum Klotho (pg/mL) 616.3 (459.9–755.5)
LDL-cholesterol (mg/dL) 119634
HDL-cholesterol (mg/dL) 51 (41–64)
Triglycerides (mg/dL) 133 (89–183)
HbA1c (NGSP) (%) 5.7 (5.5–6.0)
CRP (mg/dL) 0.05 (0.02–0.15)
eGFR (ml/min/1.73 m2) 48629
Albuminuria (mg/day) 439 (128–1381)
Serum albumin (g/dL) 3.9 (3.6–4.2)
Hemoglobin (g/dL) 12.662.2
Uric acid (mg/dL) 6.961.6
FMD (%) 4.7 (3.1–7.6)
baPWV (cm/sec) 1560 (1331–1796)
Max IMT (mm) 0.85 (0.68–1.10)
ACI (%) 4.2 (0–16.4)
ACEI, angiotensin converting enzyme inhibitor; ACI, abdominal aortic
calcification index; ARB, angiotensin receptor blocker; baPWV, brachial-ankle
pulse wave velocity; CRP, C-reactive protein; 1,25D, 1,25-dihydroxyvitamin D;
25D, 25-hydroxyvitamin D; eGFR, estimated glomerular filtration rate; FECa,
fractional excretion of calcium; FEPi, fractional excretion of phosphate; FGF23,
fibroblast growth factor 23; FMD, flow-mediated dilatation, HDL, high density
lipoprotein; IMT, intima-media thickness; LDL, low density lipoprotein; MBP,
mean blood pressure; NGSP, national glycohemoglobin standardization
program.
doi:10.1371/journal.pone.0056695.t001
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Relationship between the serum Klotho level and age,
renal function, CKD-related mineral metabolism and
markers of vascular dysfunction
Age-dependent changes were recognized in the serum Klotho
levels in patients with CKD (Figure 1A), as has been reported in
healthy subjects [27]. The serum Klotho level was significantly
correlated with the eGFR (Figure 1B) and decreased along with
CKD stages (Figure S1A). With regard to markers of CKD-
MBD, the serum Klotho level was positively correlated with the
1,25-dihydroxyvitamin D (1,25D) level (Figure 1C) and nega-
tively correlated with the log intact parathyroid hormone (PTH)
and fractional excretion of phosphate (FEPi) (Figure 1D, 1E).
The FEPi significantly increased along with declines in the eGFR
(univariate regression, r =20.7228, p,0.0001). There were no
correlations between the level of serum Klotho and the fractional
excretion of calcium (FECa) (Figure 1F) or the 25-hydroxyvita-
min D (25D) level (Figure S2C). However, correlations were
observed between the level of serum Klotho and the level of serum
calcium (r = 0.1618; p = 0.0855), the level of serum phosphate
(r =20.1454; p = 0.1426) and log intact FGF23 (r =20.1751;
p = 0.0624) (Figure S2A, Figure S2B and Figure S2D,
respectively).
We next investigated the association between the serum Klotho
level and various markers of vascular dysfunction, including flow-
mediated dilatation (FMD), a marker of nitric oxide-dependent
endothelial function, brachial-ankle pulse wave velocity (baPWV),
a marker of arterial stiffness, maximum intima-media thickness
(max IMT), a marker of atherosclerosis, and the abdominal aortic
calcification index (ACI), a marker of vascular calcification
(Figure 2). The serum Klotho levels tended to be lower in
patients with FMD,6.0% compared to those with FMD$6.0%
(p= 0.0863) (Figure 2A). The serum Klotho levels were
significantly lower in patients with PWV$1400 cm/s, max
IMT$1.1 mm and ACI.0% compared to those with
PWV,1400 cm/s, max IMT,1.1 mm and ACI= 0%, respec-
tively (Figure 2B–D).
A multivariate analysis of the determinants of signs of
vascular dysfunction, including arterial stiffness, in CKD
patients
Separate multiple logistic regression models for markers of
various signs of vascular dysfunction were analyzed (Table 2 and
Table S1, S2, S3). After adjusting for age, gender, mean blood
pressure, use of antihypertensive drugs, drinking and current
smoking, the serum Klotho level was found to be a significantly
independent predictor of baPWV$1400 cm/sec in a metabolic
model that included non-HDL cholesterol, use of antihyperlipid-
emic agents, hemoglobin A1c and use of antidiabetic agents as
other parameters (Table 2, upper panel). The serum Klotho
level was also found to be a significantly independent predictor of
baPWV$1400 cm/sec in a CKD model that included eGFR,
albuminuria and hemoglobin as other parameters (Table 2,
middle panel) and a CKD-MBD model that included serum
calcium, phosphate, intact PTH, 1,25D and FGF23 as other
parameters (Table 2, lower panel). We performed the same
analysis using multiple logistic regression models of the serum
Klotho level as a predictor of FMD$6.0%, max IMT$1.1 mm
and ACI.0%; however, the serum Klotho level was not found to
be a significant predictor of any of these parameters (Table S1,
S2, S3, respectively). Next, a multivariable logistic regression
analysis was performed to evaluate the impact of serum Klotho on
arterial stiffness assessed by baPWV in CKD patients. This model
includes candidate predictors that were selected based on Table 2.
The factors significantly associated with baPWV were age, MBP,
albuminuria and serum Klotho. The adjusted odds ratios (ORs)
for serum Klotho (per 100 pg/mL increase) and albuminuria (per
500 mg/day increase) were 0.60 (95% CI: 0.39 to 0.98;
p = 0.0075) and 1.97 (95% CI: 1.16 to 3.73; p= 0.0219),
respectively (Figure 3).
Discussion
In this study, we measured the serum Klotho levels and
determined the relationships between the serum Klotho level and
markers of CKD-MBD and vascular dysfunction, including FMD,
baPWV, max IMT and ACI in patients with CKD. We herein
provide the first evidence in CKD patients that: 1) the serum
soluble Klotho level is significantly correlated with markers of
CKD-MBD, including the levels of PTH, 1,25D and FEPi; 2)
decreased levels of serum Klotho are significantly associated with
signs of vascular dysfunction such as pronounced arterial stiffness
evaluated by baPWV; and 3) in a multivariate analysis, the serum
Klotho level was found to be an independent determinant of
marked arterial stiffness, which has been reported to be associated
with increased cardiovascular mortality and morbidity.
In this study, the group with lower levels of serum Klotho
exhibited significantly lower eGFR levels, as previously reported in
CKD patients [17] and patients on hemodialysis [34]. It has been
reported that the mRNA and protein expression levels of Klotho
are severely reduced in the kidneys of patients with chronic renal
failure compared to control subjects [35]. However, it seems that
the serum Klotho levels are not completely depleted, even in
patients with stage 5 CKD on hemodialysis [34]. This finding
suggests that a basal level of Klotho production from other organs
than the kidneys, such as the brain and parathyroid glands, might
exist in humans, as has been previously reported in mice [8,9,10].
A recent study indicated that the transcriptional suppression of
Klotho by a protein-bound uremic toxin, indoxyl sulfate, results
from CpG hypermethylation of the Klotho gene [36]. Since
indoxyl sulfate may play a significant role in the vascular disease
and higher mortality observed in CKD patients [37], epigenetic
modification of the Klotho gene by a uremic toxin such as indoxyl
sulfate might be a mechanism underlying the association between
the decline of serum Klotho levels and arterial stiffness in CKD
patients observed in the current study.
With regard to markers of CKD-MBD, the serum Klotho level
was inversely correlated with the FEPi and log intact PTH and
positively correlated with the 1,25D level. The FEPi significantly
increased along with declines in the eGFR in the CKD patients
evaluated in this study and also in the Chronic Renal Insufficiency
Cohort (CRIC) study [6]. The serum Klotho is unable to function
as a decoy receptor for FGF23, because Klotho alone does not
bind to FGF23 with high affinity. Unlike membrane Klotho,
serum Klotho cannot efficiently support FGF23-induced activa-
tion of FGF signaling [38]. Instead, serum Klotho may inhibit
Type 2a Na-phosphate co-transporter (Npt2a) by decreasing the
number of cell-surface Npt2a, thereby reducing cellular phosphate
uptake in renal proximal tubular cells [39]. The level of serum
Klotho might therefore reflect increased phosphate excretion from
the kidneys, which is one of the characteristics of disordered
mineral metabolism observed in CKD patients.
To date, several markers have been utilized to assess cardio-
vascular dysfunction in CKD patients, including FMD, baPWV,
IMT and ACI [40,41,42,43,44]. In the current study, we
demonstrated that the level of serum Klotho is an independent
determinant of arterial stiffness only defined as
baPWV$1400 cm/s, even after adjusting for age, gender, mean
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blood pressure, use of antihypertensive drugs, drinking and
smoking. In addition, serum Klotho was also a significant
predictor of arterial stiffness in the full model including
confounders such as age, MBP, diabetes mellitus, dyslipidemia,
eGFR, albuminuria, phosphate, PTH, 1,25D and FGF23, and the
adjusted odds ratio (OR) for serum Klotho (per 100 pg/mL
increase) was 0.60 (95% CI: 0.39 to 0.98; p = 0.0075). There have
been some reports discussing the associations between baPWV
and CKD-MBD parameters such as phosphate [45], 1,25D [46],
PTH [47,48] and FGF23 [49,50]; however, these associations are
inconsistent. Several reports have shown that increases in aortic
stiffness begin as early as CKD stage 2 and increase with the
progression to stages 3 and 4 [51,52]. Conversely, improvements
in aortic stiffness have been associated with improved prognoses in
patients with end-stage renal disease [53]. The role of serum
Klotho in the progression of arterial stiffness has not yet been
elucidated in human CKD; however, in vivo gene delivery of
Klotho into skeletal muscle prevents medial hypertrophy of the
aorta in an animal model of atherosclerotic disease [12]. It also
improves endothelium-dependent relaxation of the aorta in
response to acetylcholine in association with increases in nitric
oxide production, suggesting that soluble Klotho plays a protective
role against the development of vascular endothelial dysfunction.
Although the receptor for soluble Klotho located in the vascular
endothelium has not been identified, soluble Klotho regulates
calcium influx to maintain the integrity of vascular endothelial
Figure 1. Correlation between the serum Klotho levels (pg/mL) and various parameters. The relationships between the serum Klotho
levels and patient age (years) (A), estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2) (B) and markers of chronic kidney disease-mineral and
bone disorder (CKD-MBD), including 1,25-dihydroxyvitamin D (1,25D) (pg/mL) (C), log intact parathyroid hormone (PTH) (pg/mL) (D), fractional
excretion of phosphate (FEPi) (%) (E) and fractional excretion of calcium (FECa) (%) (F) are shown. The serum Klotho levels were inversely correlated
with age and positively correlated with eGFR (A, B). Regarding CKD-MBD markers, the serum Klotho levels were significantly correlated with 1,25D
and negatively correlated with log intact PTH and FEPi; however, no significant correlation was observed with FECa (C–F). (A–F) N = 114.
doi:10.1371/journal.pone.0056695.g001
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cells in a mouse model and in in vitro endothelial cell culture studies
[22]. The ‘local’ vascular Klotho in human arteries may act as an
endogenous inhibitor of vascular calcification and as a cofactor
required for vascular FGF23 signaling [31]. Conducting further
studies will therefore be necessary in order to investigate how
‘systemic’ serum Klotho interacts with the mechanisms of arterial
stiffness in human CKD.
An association between Klotho deficiency and vascular
calcification has been reported in aging mice and in a mouse
model of CKD [10,16,24]. In the assessment of vascular
calcification conducted in the current study, the levels of serum
Klotho were decreased in CKD patients with ACI.0% compared
to those in patients without aortic calcification (Figure 2D),
although the levels of serum Klotho were not significantly
correlated with the degree of ACI (Figure S2H) or were not
independent determinants of ACI (Table S3). There are two
possible reasons why the serum Klotho levels are not significantly
correlated with the degree of aortic calcification in human CKD
patients. First, soft tissue calcification in human CKD may
progress more slowly than that observed in murine CKD [16],
despite phosphorus and calcium playing major roles in the
calcification process in CKD patients. The CKD cohort in our
study comprised mostly patients with CKD of stages 1 to 3
(68.4%), which are the early to middle stages of CKD, rather than
patients with severe renal dysfunction or uremia that may induce a
more procalcific CKD phenotype [54].
Increased serum phosphorus levels are associated with cardio-
vascular disease in both patients with chronic kidney disease
(CKD) and in the general population. High phosphate levels may
play a direct role in vascular dysfunction. In the current study,
however, there were no significant correlations between the serum
phosphate levels and the FMD (r =20.0530, p = 0.5596), baPWV
(r = 0.1217, p = 0.2778), max IMT (r = 0.1030, p= 0.2695) or ACI
(r = 0.0245, p = 0.7988). Kestenbaum et al. reported a significant
increase in the mortality risk in patients with CKD with phosphate
levels higher than 3.5 mg/dL [55]. In our cohort, only 41.4% (46
out of 114) patients exhibited serum phosphate levels higher than
3.5 mg/dL, so the phosphate levels might not correlate with the
vascular dysfunction in this study. A recent report demonstrated
that a high phosphate level directly affects endothelial dysfunction
[56]. Indeed, our data suggest that there is some relationship
between the FEPi and FMD (r =20.2520, p = 0.0077), although
the correlation was not statistically significant. Another report
using an animal model indicated that changes in extracellular
phosphorus concentrations may directly modulate the vascular
smooth muscle function [57]. Based on these findings, phosphate
could still be a major direct player in the pathogenesis of the
vascular dysfunctions observed in patients with CKD.
Figure 2. Box and line plots showing the levels of serum Klotho (pg/mL) according to the stratified levels of vascular dysfunction.
They include flow-mediated dilatation (FMD) (%), a marker of endothelial dysfunction (A), ankle-brachial pulse wave velocity (baPWV) (cm/sec), a
marker of arterial stiffness (B), maximum intima-media thickness (max IMT) (mm), a marker of atherosclerosis (C), and the aortic calcification index
(ACI) (%), a marker of vascular calcification (D). The serum Klotho levels were significantly lower in patients with FMD,6.0%, PWV$1400 cm/s, max
IMT$1.1 mm and ACI.0% compared to patients with FMD$6.0%, PWV,1400 cm/s, max IMT,1.1 mm and ACI = 0%, respectively (A–D). (A) N = 70
and n= 40 in FMD,6.0% and FMD$6.0%, respectively. (B) N = 60 and n=45 in PWV,1400 cm/s and PWV$1400 cm/s, respectively. (C) N = 82 and
n= 29 in max IMT,1.1 mm and max IMT$1.1 mm, respectively. (D) N = 28 and n= 75 in ACI = 0% and ACI.0%, respectively. The boxes denote the
medians and 25th and 75th percentiles. The lines mark the 5th and 95th percentiles.
doi:10.1371/journal.pone.0056695.g002
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Membrane Klotho functions as a co-receptor for FGF23, a
bone-derived hormone that induces phosphate excretion into the
urine [19]. The presence of membrane Klotho determines the
target organs of FGF23 and its signaling since most tissues express
receptors for FGF. Nakano et al. recently reported that the serum
intact FGF23 level is the earliest indicator among various CKD-
MBD-related factors and that a high intact FGF23 level and a low
25-hydroxyvitamin D (25D) level independently predict poor renal
outcomes, even after adjusting for other MBD-related factors, in
patients with pre-dialysis CKD [58]. However, the serum Klotho
level was not evaluated in that report, and the exact functions of
serum soluble Klotho have yet to be defined [59]. Therefore,
whether an excess level of FGF23 and the occurrence of adverse
outcomes in patients with CKD are mediated by a deficiency of
serum Klotho remains unclear [60].
There have been discrepancies among the study results
concerning the correlation between the serum Klotho levels and
GFR in patients with CKD [17,32,61]. One study found that the
plasma Klotho level was not related to the kidney function in
patients with CKD, but this study population included nearly 40%
patients with diabetes mellitus (39.4%) [61]. In contrast, the serum
levels of soluble Klotho were decreased in patients with early
stages of CKD in a different study including 15.4% diabetes
mellitus cases [17]. These discrepancies may be due to two
possible causes. First, including diabetic patients in the CKD
cohort may underestimate the level of serum Klotho, since the
level of serum Klotho is lower in diabetic patients compared to
non-diabetic patients [32]. Second, several ELISA kits to detect
the level of soluble Klotho are commercially available, potentially
leading to different results in terms of the association of serum
Klotho with the renal function.
Our study has several limitations and strengths that should be
kept in mind when interpreting the results. First, the cross-
Figure 3. Multivariate odds ratio for ankle-brachial pulse wave velocity (baPWV) among patients with CKD displayed as the odds
ratio (OR) (solid boxes) with 95% confidence intervals (CIs) (horizontal limit lines). For continuous variables, the unit of change is given in
parenthesis based on the multivariate model described in Table 2. MBP, mean blood pressure; eGFR, estimated glomerular filtration rate; PTH,
parathyroid hormone; 1,25D, 1,25-dihydroxyvitamin D; FGF23, fibroblast growth factor 23.
doi:10.1371/journal.pone.0056695.g003
Table 2. A multiple logistic regression analysis of predictors
of PWV$1400 cm/sec.
b p
Metabolic model
serum Klotho 20.00404 0.0315
non HDL 0.00226 0.8185
antihyperlipidemic drugs 0.42663 0.2660
HbA1c (NGSP) 0.43333 0.4369
antidiabetic drugs 0.43224 0.5107
CKD model
serum Klotho 20.00349 0.0431
eGFR 0.01367 0.3911
albuminuria 0.00062 0.1904
Hemoglobin 20.01483 0.9467
CKD-MBD model
serum Klotho 20.00431 0.0368
serum calcium 20.96331 0.4039
serum phosphate 20.65510 0.4178
intact PTH 20.00625 0.2903
1,25D 0.00367 0.8244
FGF23 20.00052 0.6933
Adjusted for age, gender, mean blood pressure, antihypertensive drug use,
drinking and current smoking. CKD, chronic kidney disease; 1,25D, 1,25-
dihydroxyvitamin D; eGFR, estimated glomerular filtration rate; FGF23,
fibroblast growth factor 23; HDL, high density lipoprotein; MBD, mineral and
bone disorder; NGSP, national glycohemoglobin standardization program.
doi:10.1371/journal.pone.0056695.t002
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sectional nature of our observations precluded making any cause-
effect inferences about the relationship between the serum Klotho
level and arterial stiffness in CKD patients. Second, we lacked data
regarding the patients’ dietary phosphorus intake, a critical factor
for CKD-MBD and the CKD-associated incidence of CVD,
which may be related to the serum Klotho level. However, this
weakness is, in part, offset by the criteria of our study because
patients who were being treated with vitamin D or phosphate
binders were excluded.
In conclusion, the serum Klotho level was found to significantly
correlate with markers of CKD-MBD and is an independent
biomarker of arterial stiffness in patients with CKD. Further
studies are required to elucidate which intervention(s) can
modulate the level of serum Klotho, as has been reported in
rodents [13,62,63], and whether any interventions to increase or
maintain the serum Klotho level can prevent cardiovascular events
and mortality in CKD patients.
Subjects and Methods
Subjects
The subjects in this study were patients admitted to the Renal
Unit of Okayama University Hospital. All patients were diagnosed
with CKD according to their estimated glomerular filtration rate
(eGFR) and the presence of kidney injury as defined by the
National Kidney Foundation K/DOQI Guidelines [64,65].
Hypertension was defined as systolic blood pressure
(SBP)$140 mmHg or diastolic blood pressure (DBP)$90 mmHg
or the use of antihypertensive drugs. The eGFR was calculated
according to the simplified version of the Modification of Diet in
Renal Disease (MDRD) formula [eGFR=1946(sCr)21.0946(a-
ge)20.287(if female60.739)] [66]. Smoking status (current smoker
vs. non-smoker) was determined from a medical interview.
Current drinking was defined as drinking alcohol at least two
times per week in the last year. All procedures in the present study
were carried out in accordance with institutional and national
ethical guidelines for human studies, and guidelines proposed in
the Declaration of Helsinki. The ethics committee of Okayama
University Graduate School of Medicine, Dentistry and Pharma-
ceutical Sciences approved the study. Written informed consent
was obtained from each subject. This study was registered with the
Clinical Trial Registry of the University Hospital Medical
Information Network (registration number UMIN000003614).
According to the established protocol, we excluded any patients
with established atherosclerotic complications (coronary artery
disease, congestive heart failure or peripheral vascular disease).
Patients with nephrotic syndrome and patients who were being
treated with vitamin D or phosphate binders were excluded. None
of the patients had an acute infection at the time of the study.
Laboratory measurements
Each subject’s arterial blood pressure was measured by a
physician after a 10 minute resting period to obtain the systolic
and diastolic pressures. The mean blood pressure (MBP) was
calculated as DBP+(SBP2DBP)/3. All samples were obtained
from patients in the morning after 12 hours of fasting. The soluble
a-Klotho (Klotho) concentrations in the serum were measured
using an ELISA system (Immuno-Biological Laboratories,
Gunma, Japan) [27]. The serum levels of intact FGF23 were
determined using a commercial sandwich ELISA kit (Kainos
Laboratories, Inc., Tokyo, Japan). The serum levels of total
protein, albumin, creatinine, calcium, inorganic phosphate and
glucose, as well as the urinary levels of albumin, creatinine,
calcium and inorganic phosphate, were measured in all patients.
The serum levels of 1,25-dihydroxyvitamin D (1,25D) and 25-
hydroxyvitamin D (25D) were measured using a radioimmunoas-
say and the serum intact PTH levels were measured using an
immunoradiometric assay. The fractional excretion of phosphorus
(FEPi) and calcium (FECa) were calculated as (urine miner-
al6serum creatinine)/(serum mineral6urine creatinine).
Vascular assessments
Endothelial dysfunction. Flow-mediated dilatation (FMD)
and endothelium-independent vasodilatation (nitroglycerin-medi-
ated dilatation; NMD) of the brachial artery were assessed
noninvasively, as previously described [44]. The subjects were
instructed to fast for at least 12 hours before testing and to abstain
from smoking and ingesting alcohol, caffeine or antioxidant
vitamins prior to testing. We obtained ultrasound measurements
according to the guidelines for ultrasound assessment of the FMD
of the brachial artery. Using a 10-MHz linear array transducer
probe, the longitudinal image of the right brachial artery was
recorded at baseline and then continuously from 30 seconds
before to at least two minutes after the cuff deflation that followed
suprasystolic compression (50 mmHg above systolic blood pres-
sure (SBP)) of the right forearm for five minutes. The diastolic
diameter of the brachial artery was determined semi-automatically
using an instrument equipped with a software program for
monitoring the brachial artery diameter (Unex Co. Ltd., Nagoya,
Japan). The FMD was estimated as the percent change in the
diameter over the baseline value at maximal dilation during
reactive hyperemia. A total of 10 minutes were allowed to elapse
for vessel recovery, after which a further resting scan was taken.
Then, 0.3 mg of nitroglycerin was administered, and a final scan
was performed five minutes later. We defined patients having
endothelial dysfunction as those with FMD,6.0% in the current
study based on previous reports [44,67,68].
Measurement of intima-media thickness
(IMT). Ultrasonography of the carotid artery was performed
using a high resolution real-time scanner with a 7.5 MHz
transducer, as previously described [40]. The examination was
performed with the subject in the supine position, and the carotid
bifurcation, as well as the common carotid artery, were scanned on
both sides. The maximum IMT value was measured as follows.
The carotid artery was scanned in the longitudinal and transverse
directions. The site of the most advanced atherosclerotic lesion
that showed the greatest distance between the lumen-intima
interface and the media-adventitia interface was located in both
the right and left carotid arteries. When plaque was detected on
ultrasonography, it was observed as localized thickening rather
than a circumferential change in the vessel wall. The greatest
thickness of the intima-media complex (including plaque) was used
for the maximum IMT value. We identified patients having
atherosclerosis based on atheromatous plaques of focal increases in
IMT$1.1 mm in accordance with a prior study that showed the
normal limit of IMT to be #1.0 mm [69].
Measurement of ankle-brachial pulse wave velocity
(baPWV). Pulse wave velocity (PWV) measurements were
obtained at the bedside of each subject using a volume
plethysmographic apparatus (FORM/ABI; Colin, Komaki, Japan)
after the subject had rested in the supine position for at least five
minutes, as previously described [40]. This instrument allows
simultaneous recording of the baPWV and the brachial and ankle
BPs on both sides, in addition to recording an electrocardiogram
and heart sounds. We defined patients having arterial stiffness as
those with baPWV$1400 since a baPWV$1400 cm/sec is an
independent variable of the risk stratification according to the
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Framingham score and for the discrimination of patients with
atherosclerotic cardiovascular disease [70].
Measurement and calculation of the aortic calcification
index (ACI). The ACI was determined as previously described
[42,43]. A non-contrast CT scan of the abdominal aorta was
performed. Calcification of the abdominal aorta above the
bifurcation of the common iliac arteries was evaluated semi-
quantitatively in 10 CT slices at 1 cm intervals. Calcification was
considered to be present if an area $1 mm2 displayed a density
$130 Hounsfield units. The cross-section of the abdominal aorta
on each slice was divided into 12 segments radially. A segment
containing an aortic wall with calcification in any section was
defined as having aortic calcification. The number of calcified
segments was counted in each slice and divided by 12. The values
thus obtained for the 10 slices were added together, divided by 10
(the number of slices inspected) and then multiplied by 100 to
express the result as a percentage: ACI (%) = (total score for
calcification in all slices)/(12 [number of segments in each
slice]610 [number of slices])6100. The ACI was used as a
marker for the extent of aortic calcification. We defined CKD
patients having abdominal calcification as those with ACI.0%, as
described previously [42,43].
Statistical analysis
Non-normally distributed variables were expressed as the median
(interquartile range) and normally distributed variables were
expressed as the mean 6 SD as appropriate. A value of P,0.05
was considered to be statistically significant. Differences between
groups were analyzed using Student’s t-test and the Mann-Whitney
U-test as appropriate. The Spearman rank correlation was used to
determine the correlations between two variables. A multiple
logistic regression analysis was applied to test the independent links
between the vascular function and potential functional correlates of
the outcome variables [71,72]. A multivariable logistic regression
analysis was performed to determine the predictors of baPWV. This
multivariate model was built using pre-specified variables including
age, gender, MBP, diabetes mellitus, dyslipidemia, eGFR, albu-
minuria, phosphate, PTH, 1,25D, FGF23 and serumKlotho. The P
values, odds ratios (ORs) and corresponding two-sided 95%
confidence intervals (CIs) for the predictors are presented. The
statistical analyses were performed using the JMP software package
release 8 (SAS Institute Inc., Cary, NC, USA).
Supporting Information
Figure S1 Box and line plots showing the levels of serum
Klotho (pg/mL) according to the estimated glomerular
filtration rate (eGFR) (mL/min/1.73 m2) or the levels of
serum log intact fibroblast growth factor 23 (FGF23)
(pg/mL) according to the estimated glomerular filtra-
tion rate (eGFR) (mL/min/1.73 m2). The serum soluble
Klotho levels significantly decreased in association with declines in
eGFR (A), while the log-transformed intact FGF23 levels
significantly increased in association with declines in eGFR (B).
(A) serum Klotho levels, eGFR$90 (stage 1), 799.0 (670.6–940.9);
eGFR 60–89 (stage 2), 637.4 (546.2–637.4); eGFR 30–59 (stage 3),
595.4 (498.8–773.9); eGFR 15–29 (stage 4), 578.3 (425.9–751.0);
eGFR 0–14 (stage 5), 525.1 (389.0–661.4) pg/mL. (A, B)
eGFR$90, n= 11; 60–89, n= 36; 30–59, n = 31; 15–29, n= 16,
0–14, n= 20. *, **, *** and **** indicate p,0.05, p,0.01,
p,0.005 and p,0.001, respectively. The boxes denote the
medians and 25th and 75th percentiles. The lines mark the 5th
and 95th percentiles.
(TIF)
Figure S2 Correlation between the serum Klotho levels
(pg/mL) and the other markers of chronic kidney
disease-mineral and bone disorder (CKD-MBD). They
include calcium (mg/dL) (A), phosphate (mg/dL) (B), 25-hydro-
xyvitamin D (25D) (C) and log intact fibroblast growth factor 23
(FGF23) (D) and various markers of vascular dysfunction,
including flow-mediated dilatation (FMD) (%) (E), ankle-brachial
pulse wave velocity (baPWV) (cm/sec) (F), maximum intima-
media thickness (max IMT) (mm) (G) and the aortic calcification
index (ACI) (%) (H). The serum Klotho levels tended to be
positively correlated with calcium and phosphate and negatively
correlated with log intact FGF23, while no significant association
was observed between the serum Klotho levels and 25D (A–D).
Regarding markers of vascular dysfunction, the serum Klotho
levels were positively correlated with FMD and negatively
correlated with baPWV and max IMT, while the correlation
between the serum Klotho levels and ACI was not significant (E–
H). (A, B, D, E–H) N= 114. (C) N= 58.
(TIF)
Figure S3 Multivariate odds ratio for flow-mediated
dilatation (FMD) among patients with CKD displayed as
the odds ratio (OR) (solid boxes) with 95% confidence
intervals (CIs) (horizontal limit lines). For continuous
variables, the unit of change is given in parenthesis based on the
multivariate model described in Table S1. MBP, mean blood
pressure; eGFR, estimated glomerular filtration rate; PTH,
parathyroid hormone; 1,25D, 1,25-dihydroxyvitamin D; FGF23,
fibroblast growth factor 23.
(TIF)
Figure S4 Multivariate odds ratio for maximum intima-
media thickness (max IMT) among patients with CKD,
displayed as odds ratio (OR) (solid boxes) with 95%
confidence intervals (CIs) (horizontal limit lines). For
continuous variables, unit of change is given in parenthesis based
on the multivariate model described in Table S2. MBP, mean
blood pressure; eGFR, estimated glomerular filtration rate; PTH,
parathyroid hormone; 1,25D, 1,25-dihydroxyvitamin D; FGF23,
fibroblast growth factor 23.
(TIF)
Figure S5 Multivariate odds ratio for aortic calcifica-
tion index (ACI) among patients with CKD displayed as
the odds ratio (OR) (solid boxes) with 95% confidence
intervals (CIs) (horizontal limit lines). For continuous
variables, the unit of change is given in parenthesis based on the
multivariate model described in Table S3. MBP, mean blood
pressure; eGFR, estimated glomerular filtration rate; PTH,
parathyroid hormone; 1,25D, 1,25-dihydroxyvitamin D; FGF23,
fibroblast growth factor 23.
(TIF)
Table S1 A multiple logistic regression analysis of
predictors of FMD$6.0%.
(DOC)
Table S2 A multiple logistic regression analysis of
predictors of max IMT$1.1 mm.
(DOC)
Table S3 A multiple logistic regression analysis of
predictors of ACI.0%.
(DOC)
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